Transgenic News and Research

RSS

Effects of COVID-19 treatment best with combination therapy

There is a steadily growing arsenal of drugs for COVID-19. Researchers from Charité – Universitätsmedizin Berlin, the Max Delbrück Center for Molecular Medicine (MDC) and Freie Universität (FU) Berlin have studied the mechanisms of action of antiviral and anti-inflammatory drugs.

15 Apr 2022

Insights into the pathogenesis of the previous and circulating SARS-CoV-2 variants in mice

A recent article presented the diverse pathogenesis of SARS-CoV-2 variants of concern in a humanized mouse model.

7 Apr 2022

Researchers identify novel SARS-CoV-2 Delta-Omicron recombinant strain in Europe

A new study presented the rapid profiling of a SARS-CoV-2 Delta-Omicron recombinant sequence from Europe.

6 Apr 2022

Mosaic-8 RBD-nanoparticles show promise as a vaccine candidate for SARS-CoV-2 and potential sarbecoviruses spillovers

Researchers designed nanoparticles representing RBDs of the S protein of animal sarbecoviruses and SARS-CoV-2 to evaluate their potential as a pan-sarbecovirus vaccine candidate.

31 Mar 2022

Chemical in leafy greens could prevent infections by coronaviruses including SARS-CoV-2

Researchers discuss the use of the isothiocyanate sulforaphane for the treatment of both SARS-CoV-2 and HCoV-OC43 infections.

30 Mar 2022

ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

Researchers demonstrated the inhalation of an ACE2 decoy receptor, sACE22.v2.4-IgG1, increases survival and ameliorates lung injury in K18-hACE2 transgenic mice.

30 Mar 2022

Tuberculosis infection protects mice against COVID-19

To study if prior Mtb infection affects the response to CoV2 infection, K18-hACE2 (ACE2) and C57BL/6 (B6) mice were infected with Mtb, and post thirty days, were exposed to CoV2.

27 Mar 2022

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

A recent study presented topologically engineered fragment crystallizable-fusion proteins and antibodies as therapeutic options for diseases like human coronaviruses infections and cancers.

25 Mar 2022

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

A team of international scientists has developed an mRNA-based coronavirus disease 2019 (COVID-19) vaccine encoding the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant. The vaccine candidate has shown high efficacy in inducing neutralizing antibodies and protecting against delta infection in mice. The study is currently available on the bioRxiv* preprint server.

24 Mar 2022

Monoclonal antibodies found to prevent lung inflammation in SARS-CoV-2-Omicron-infected mice

Researchers investigated how monoclonal antibodies, S309 and AZD7442, reduced lung infection in mice infected with the SARS-CoV-2 new variant of concern Omicron's BA.1, BA.1.1, and BA.2 sublineages.

23 Mar 2022

Lettuce could protect astronauts from bone density loss in microgravity

Astronauts might one day grow and eat genetically modified plants to ward off disease associated with long spaceflights. Researchers at the University of California, Davis College of Engineering have developed a transgenic, or genetically modified, lettuce producing a drug to protect against bone density loss in microgravity.

22 Mar 2022

Study evaluates COVID-19 vaccination with recombinant accessory protein-deficient SARS-CoV-2

Researchers assessed the impact of recombinant accessory protein-deficient severe acute respiratory syndrome coronavirus 2 immunization against SARS-CoV-2 transmission and disease severity.

18 Mar 2022

Researchers receive grant to find answers to taste loss in COVID patients

Up to 80% of individuals who've had COVID-19 report temporary or lasting changes in their sense of taste, and scientists are working to better understand the biological basis of why, including whether our taste buds are a direct virus target.

15 Mar 2022

Do anti-nucleocapsid antibodies affect COVID-19 immune reactions?

Researchers have been investigating the potential for vaccines and treatments against the nucleocapsid protein of SARS-CoV-2.

15 Mar 2022

Protection against SARS-CoV-2 Omicron variant by hetero-bivalent nanobodies

A new study investigated the broad-spectrum protection provided by hetero-bivalent nanobodies against SARS-CoV-2 variants of concern, such as Omicron.

14 Mar 2022

Potent pan-β-CoV human monoclonal antibody has in vivo activity in multiple animal models

Researchers evaluated the efficacy of viral spike domain 2-specific human monoclonal antibodies delivered intranasally, against all beta coronaviruses in hamsters and mice.

11 Mar 2022

Study finds chimeric mRNA induces potent and broadly acting neutralizing antibodies against SARS-CoV-2 variants

Researchers explored strategies to develop an mRNA-based COVID-19 vaccine that could elicit safer and wider protection against SARS-CoV-2 variants of concern.

10 Mar 2022

CRIPSR identifies cell-type-specific ACE2 modifiers

Researchers compile a list of candidate genes to identify the surface abundance of functional regulators of ACE2.

9 Mar 2022

Manipulating carotenoids can improve plant growth, stress tolerance and increase yield

Manipulating the content of carotenoids, such as ß-carotene, has been found to improve plant growth and increase yield and tolerance to abiotic stresses such as drought and salinity.

7 Mar 2022

Angiotensin-converting enzyme 2-based mutant decoy effectively reduces COVID-19 in mice

Researchers engineered a mutant ACE2 decoy that effectively protected human lung epithelia from SARS-CoV-2 infection by competitively binding to its spike protein.

3 Mar 2022